Administration of probiotic kefir to mice with Clostridium difficile infection exacerbates disease.

Authors :: Spinler JK
Brown A
Ross CL
Boonma P
Conner ME
Savidge TC
Source :: Anaerobe [Anaerobe] 2016 Aug; Vol. 40, pp. 54-7. Date of Electronic Publication: 2016 May 11.
Publication Year :: 2016
Abstract: Lifeway(®) kefir, a fermented milk product containing 12 probiotic organisms, is reported to show promise as an alternative to fecal microbiota transplantation for recurrent Clostridium difficile infection (CDI). We employed a murine CDI model to study the probiotic protective mechanisms and unexpectedly determined that kefir drastically increased disease severity. Our results emphasize the need for further independent clinical testing of kefir as alternative therapy in recurrent CDI.<br /> (Copyright © 2016 Elsevier Ltd. All rights reserved.)

Subjects :: Animals
Clostridioides difficile growth & development
Clostridioides difficile pathogenicity
Colony Count, Microbial
Disease Models, Animal
Disease Progression
Enterocolitis, Pseudomembranous microbiology
Enterocolitis, Pseudomembranous mortality
Female
Gastrointestinal Microbiome drug effects
Mice
Mice, Inbred C57BL
Severity of Illness Index
Survival Analysis
Clostridioides difficile drug effects
Enterocolitis, Pseudomembranous pathology
Kefir adverse effects
Probiotics adverse effects

Full Text Access

Tools